NCT04404569: Continued Treatment for Participants Enrolled in Studies of BXQ-350

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Enrolling by invitation
Phase 1
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 1 Year and older (Child, Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have completed the End of Study visit of the prior Bexion-sponsored BXQ-350 clinical study

Comments are closed.

Up ↑